Human Organoids Market

The global human organoids market is projected to reach USD 0.90 billion by 2031 from USD 0.29 billion in 2026, at a CAGR of 25.6%. The human organoids market is expected to expand during 2026–2031 as drug developers adopt human-relevant models for screening, safety testing, and disease research. The study covers finished organoid models, model development, and organoid-based testing services for medical and pharmaceutical applications. Separately sold culture inputs and instruments are excluded. The FDA’s April 2025 roadmap supports evaluating validated alternatives to animal testing.

Key players in this market include Merck KGaA (Germany), Danaher Corporation (US), Samsung Biologics (South Korea), WuXi AppTec (China), and Evotec (Germany). Their recent acquisitions and service launches are expanding capabilities in patient-derived models, scalable organoid production, and research services related to disease-relevant drug development.

To know about the assumptions considered for the study download the pdf brochure

Merck KGaA (Germany)

Merck KGaA participates through HUB Organoids (Netherlands), following the acquisition agreement announced in December 2024 and completion of the acquisition in January 2025. HUB offers patient-derived organoid services spanning custom model and assay development, drug screening, and co-clinical testing. Its healthy and diseased tissue models help pharmaceutical and biotechnology customers investigate efficacy, toxicity, and patient variability in oncology and other therapeutic research.

Danaher Corporation (US)

Danaher participates through Molecular Devices (US), which acquired Cellesce (UK) in December 2022. Its custom organoid generation and expansion services supply standardized, assay-ready patient-derived organoids for downstream screening. Controlled bioprocessing helps researchers obtain consistent batches and overcome limited model availability, supporting the use of organoids in high-throughput drug discovery programs.

Samsung Biologics (South Korea)

Samsung Biologics launched Samsung Organoids in June 2025, extending its services into preclinical research. The platform provides patient-derived tumor organoids for drug screening across colorectal, lung, liver, gastric, and breast cancers. Organoid response data, multi-omics, and predictive analysis support target validation, lead selection, and biomarker discovery, helping customers investigate candidate efficacy and patient-specific differences in oncology.

WuXi AppTec (China)

WuXi AppTec participates through WuXi Biology, which develops patient-derived xenograft-derived organoids for in vitro oncology research. Models cover colorectal, head and neck, lung, pancreatic, and gastric cancers. Molecular characterization and pharmacological validation support high-throughput and high-content screening of targeted and immuno-oncology therapies. The study includes organoid model development and testing, with animal-based xenograft studies excluded.

Evotec (Germany)

Evotec’s renal research offering includes iPSC-derived kidney organoids and assay systems for disease modeling, including polycystic kidney disease. The company also investigates multilineage organoid technologies to improve physiological relevance. These capabilities complement its broader discovery platforms and support disease-specific research and therapeutic evaluation.

Market Ranking

Market positions in human organoids depend on access to clinically characterized models, reproducibility, disease coverage, and the ability to supply models or deliver testing services at scale. Acquisitions are broadening the capabilities of diversified companies, while specialist providers compete through proprietary model collections and tailored assays. These factors provide a basis for assessing competitive positioning across the study’s product and service offerings.

Merck KGaA (Germany), through HUB Organoids (Netherlands), combines patient-derived models with custom development and drug screening services. Danaher Corporation (US), through Molecular Devices (US), focuses on scalable production and supply of standardized, assay-ready organoids. Their capabilities address different customer needs: outsourced disease-specific studies and reliable access to organoids for screening programs, respectively. Model quality and consistency are central to both approaches.

Samsung Biologics (South Korea) focuses on an organoid-based drug screening service that provides data-driven, multi-modal analysis of candidate molecules for drug discovery and development. WuXi AppTec (China) provides molecularly characterized xenograft-derived organoid models for oncology screening. Evotec (Germany) contributes kidney organoid models and assay expertise for renal disease research. Together, these capabilities illustrate competition based on therapeutic focus, model characterization, and research services, alongside Merck’s patient-derived organoid expertise and Danaher’s scalable model production.

Specialist organoid developers and regional research service providers also contribute to the market through customized models and application-specific testing. Opportunities include expanding disease and donor coverage, improving batch consistency, and supplying models for personalized medicine research. Providers that demonstrate reliable performance and offer practical access to finished organoids or outsourced testing can address the needs of biotechnology companies and academic research teams.

Related Reports:

Human Organoids Market by Offering (Models, Service), Type (Liver, Kidney, Heart), Culture Type (ECM, Suspension), Source (ASCs, ESCs), Disease Area (Oncology, GI, Neurology), Application (Screening, Toxicity, Efficacy), End User - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]